Washington-based gene therapy developer Regenxbio Inc. has shored up key intellectual property rights and relationships supporting its preclinical therapies for the rare genetic diseases Hurler and Hunter syndromes, executing two exclusive new license and research agreements with the universities of Pennsylvania and Minnesota.